Markus Hartenfeller - Concepedia

Author

Markus Hartenfeller

École Polytechnique Fédérale de Lausanne

Also Known As

M Hartenfeller, M. Hartenfeller, Markus Hartenfeller

Publications

962

Citations

H-Index

Concepts

All Affiliations

École Polytechnique Fédérale de Lausanne ETH Zurich Novartis (Switzerland)Goethe University Frankfurt

About

Markus Hartenfeller is an author at École Polytechnique Fédérale de Lausanne specializing in drug discovery, drug design, and medicine.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	4	4	207
2	Engineering	3	3	213
3	Biomolecular Engineering	3	3	213
4	Natural Sciences	2	2	206
5	Biochemistry	2	2	187

Markus Hartenfeller

Publications

677

Citations

H-Index

Page 1

	Year	Citations
DOGS: Reaction-Driven de novo Design of Bioactive Compounds Markus Hartenfeller, Heiko Zettl, Miriam Walter, PLoS Computational Biology	2012	261
A Collection of Robust Organic Synthesis Reactions for <i>In Silico</i> Molecule Design Markus Hartenfeller, Martin Eberle, Peter Meier, Journal of Chemical Information and Modeling Combinatorial ChemistryFocused CollectionMedicinal ChemistryBioorganic ChemistryEngineering	2011	119
Enabling future drug discovery by <i>de novo</i> design Markus Hartenfeller, Gisbert Schneider Wiley Interdisciplinary Reviews Computational Molecular Science Drug TargetMolecular BiologyVirtual Compound ConstructionMolecular DesignMedicinal Chemistry	2011	87
Concept of Combinatorial <i>De Novo</i> Design of Drug‐like Molecules by Particle Swarm Optimization Markus Hartenfeller, Ewgenij Proschak, Andreas Schüller, Chemical Biology & Drug Design Combinatorial ChemistryEngineeringMolecular BiologyComputational ChemistryMolecular Design	2008	68
Probing the Bioactivity-Relevant Chemical Space of Robust Reactions and Common Molecular Building Blocks Markus Hartenfeller, Martin Eberle, Peter Meier, Journal of Chemical Information and Modeling	2012	40
Reaction-Driven <i>De Novo</i> Design, Synthesis and Testing of Potential Type II Kinase Inhibitors Gisbert Schneider, Tim Geppert, Markus Hartenfeller, Future Medicinal Chemistry	2011	40
‘Fuzziness’ in pharmacophore-based virtual screening and de novo design Alexander Klenner, Markus Hartenfeller, Petra Schneider, Drug Discovery Today Technologies Virtual ScreeningDrug DesignMedicineRational Drug DesignPharmacology	2010	26
Drugs by Numbers: Reaction‐Driven De Novo Design of Potent and Selective Anticancer Leads Birgit Spänkuch, Sarah Keppner, Lisa Lange, Angewandte Chemie International Edition Drug TargetEngineeringChemoprevention StrategyDesign Software DogsPharmaceutical Chemistry	2012	26
Repurposing de novo designed entities reveals phosphodiesterase 3B and cathepsin L modulators Tiago Rodrigues, Yen‐Chu Lin, Markus Hartenfeller, Chemical Communications	2015	10

Page 1